Vuong Trieu
Chief Executive Officer at ONCOTELIC THERAPEUTICS, INC.
Net worth: 4 M $ as of 2024-04-29
Profile
Dr. Vuong Trieu is a Chairman, President & Chief Executive Officer at Oncotelic Therapeutics, Inc., a Chairman, President & Chief Executive Officer at Oncotelic, Inc., a Chairman at IthenaPharma, Inc., a Chief Executive Officer at Autotelic, Inc., a Chief Operating Officer at LipoMedics, Inc., a Member at American Association for Cancer Research, a Member at American Society of Clinical Oncology, Inc., a Member at The Endocrine Society and a President & Director at Stocosil, Inc. He is on the Board of Directors at Stocosil, Inc. Dr. Trieu was previously employed as an Executive Chairman & Chief Executive Officer by Marina Biotech, Inc., a Chief Executive Officer by IgDraSol, Inc., a Pharmacology Director by Abraxis BioScience, Inc., and a Director-Cardiovascular Biology Program by Parker Hughes Institute.
He also served on the board at Sorrento Therapeutics, Inc., Marina Biotech, Inc. and Cenomed, Inc. He received his doctorate degree from the University of Oklahoma.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ONCOTELIC THERAPEUTICS INC
24.75% | 2024-04-11 | 98,916,746 ( 24.75% ) | 4 M $ | 2024-04-29 |
ADHERA THERAPEUTICS INC
0.06% | 2023-04-27 | 4,311 ( 0.06% ) | 30 $ | 2024-04-29 |
Vuong Trieu active positions
| Companies | Position | Start |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Chief Executive Officer | 2019-04-21 |
Stocosil, Inc.
 Stocosil, Inc. Pharmaceuticals: MajorHealth Technology Stocosil, Inc. operates as a pharmaceutical company which develops, manufactures and markets drug therapies. The firm delivers next generation products that treat the double-threat of hypertension and high cholesterol. The company was founded in December 2014 and is headquartered in City of Industry, CA. | President | - |
LipoMedics, Inc.
 LipoMedics, Inc. Pharmaceuticals: MajorHealth Technology LipoMedics, Inc. develops personalized paclitaxel therapy based on its proprietary Therapeutic Drug Monitoring (TDM) device and its platform for delivery of water insoluble drugs including paclitaxel. The company is headquartered in Fort Worth, TX. | Chief Operating Officer | - |
IthenaPharma, Inc.
 IthenaPharma, Inc. Miscellaneous Commercial ServicesCommercial Services IthenaPharma, Inc. engages in the development and commercialization of combination products for pain, arthritis, hypertension, and cancer. The company was founded on September 30, 2014 and is headquartered in Fountain Valley, CA. | Chairman | - |
Oncotelic, Inc.
 Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Chief Executive Officer | 2014-12-31 |
Autotelic, Inc.
 Autotelic, Inc. Pharmaceuticals: MajorHealth Technology Autotelic, Inc. manufactures therapeutics drugs. Its Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. The company was founded in 2013 and is headquartered in Costa Mesa, CA. | Chief Executive Officer | - |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Corporate Officer/Principal | - |
American Association for Cancer Research
 American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
| The Endocrine Society | Corporate Officer/Principal | - |
Former positions of Vuong Trieu
| Companies | Position | End |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Vuong Trieu
| University of Oklahoma | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| ADHERA THERAPEUTICS, INC. | Health Technology |
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| Private companies | 12 |
|---|---|
IgDraSol, Inc.
 IgDraSol, Inc. Pharmaceuticals: MajorHealth Technology Part of Cambridge Equities LP, IgDraSol, Inc. is a company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million. | Health Technology |
| The Endocrine Society | |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
Autotelic, Inc.
Autotelic, Inc. Pharmaceuticals: MajorHealth Technology Autotelic, Inc. manufactures therapeutics drugs. Its Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. The company was founded in 2013 and is headquartered in Costa Mesa, CA. | Health Technology |
Oncotelic, Inc.
Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Health Technology |
Stocosil, Inc.
Stocosil, Inc. Pharmaceuticals: MajorHealth Technology Stocosil, Inc. operates as a pharmaceutical company which develops, manufactures and markets drug therapies. The firm delivers next generation products that treat the double-threat of hypertension and high cholesterol. The company was founded in December 2014 and is headquartered in City of Industry, CA. | Health Technology |
IthenaPharma, Inc.
IthenaPharma, Inc. Miscellaneous Commercial ServicesCommercial Services IthenaPharma, Inc. engages in the development and commercialization of combination products for pain, arthritis, hypertension, and cancer. The company was founded on September 30, 2014 and is headquartered in Fountain Valley, CA. | Commercial Services |
LipoMedics, Inc.
LipoMedics, Inc. Pharmaceuticals: MajorHealth Technology LipoMedics, Inc. develops personalized paclitaxel therapy based on its proprietary Therapeutic Drug Monitoring (TDM) device and its platform for delivery of water insoluble drugs including paclitaxel. The company is headquartered in Fort Worth, TX. | Health Technology |
| Cenomed, Inc. | |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
| Parker Hughes Institute |
- Stock Market
- Insiders
- Vuong Trieu
